Recent Investment Analysts’ Ratings Updates for Stoke Therapeutics (STOK)

Stoke Therapeutics (NASDAQ: STOK) has recently received a number of price target changes and ratings updates:

• 11/19/2025 – Stoke Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Stoke Therapeutics was upgraded by analysts at Chardan Capital to a “strong-buy” rating.
• 11/13/2025 – Stoke Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/7/2025 – Stoke Therapeutics was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating.
• 11/5/2025 – Stoke Therapeutics had its price target raised by analysts at Canaccord Genuity Group Inc. from $24.00 to $28.00. They now have a “buy” rating on the stock.
• 11/5/2025 – Stoke Therapeutics had its price target raised by analysts at Wedbush from $22.00 to $32.00. They now have an “outperform” rating on the stock.
• 11/5/2025 – Stoke Therapeutics had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $39.00 price target on the stock.
• 11/3/2025 – Stoke Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $15.00 to $25.00. They now have a “neutral” rating on the stock.
• 10/13/2025 – Stoke Therapeutics had its price target raised by analysts at BTIG Research from $28.00 to $39.00. They now have a “buy” rating on the stock.
• 10/10/2025 – Stoke Therapeutics had its price target raised by analysts at Needham & Company LLC from $22.00 to $35.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Stoke Therapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity

In related news, General Counsel Jonathan Allan sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $25.07, for a total transaction of $250,700.00. Following the transaction, the general counsel owned 11,831 shares of the company’s stock, valued at approximately $296,603.17. This represents a 45.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Adrian R. Krainer sold 40,472 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $26.98, for a total value of $1,091,934.56. Following the completion of the transaction, the director owned 364,246 shares of the company’s stock, valued at $9,827,357.08. This trade represents a 10.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 211,488 shares of company stock valued at $5,072,884. 9.50% of the stock is owned by corporate insiders.

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.